[{"address1": "200 Arsenal Yards Boulevard", "address2": "Suite 230", "city": "Watertown", "state": "MA", "zip": "02472", "country": "United States", "phone": "857 285 5300", "website": "https://www.kymeratx.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company develops STAT6, a Type 2 inflammation in allergic diseases; and TYK2, a treatment for inflammatory bowel disease, psoriasis, psoriatic arthritis, and lupus. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.", "fullTimeEmployees": 181, "companyOfficers": [{"maxAge": 1, "name": "Dr. Bruce L. Booth DPHIL, Ph.D.", "age": 49, "title": "Co-Founder & Independent Chairman", "yearBorn": 1974, "fiscalYear": 2023, "totalPay": 75000, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Nello  Mainolfi M.D., Ph.D.", "age": 44, "title": "Co-Founder, President, CEO & Director", "yearBorn": 1979, "fiscalYear": 2023, "totalPay": 1075600, "exercisedValue": 457971, "unexercisedValue": 20455824}, {"maxAge": 1, "name": "Mr. Bruce N. Jacobs CFA", "title": "Chief Financial Officer", "fiscalYear": 2023, "totalPay": 671200, "exercisedValue": 249766, "unexercisedValue": 5641756}, {"maxAge": 1, "name": "Dr. Jeremy G. Chadwick Ph.D.", "age": 60, "title": "Chief Operating Officer", "yearBorn": 1963, "fiscalYear": 2023, "totalPay": 614498, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Ellen V. Chiniara Esq., J.D.", "age": 64, "title": "Chief Legal Officer & Corporate Secretary", "yearBorn": 1959, "fiscalYear": 2023, "totalPay": 640345, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Jared A. Gollob M.D.", "age": 58, "title": "Chief Medical Officer", "yearBorn": 1965, "fiscalYear": 2023, "totalPay": 723600, "exercisedValue": 0, "unexercisedValue": 4995031}, {"maxAge": 1, "name": "Ms. Karen  Weisbach", "title": "Head of People & Culture", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Juliet  Williams B.A Ph.D.", "title": "Head of Research", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 3, "boardRisk": 8, "compensationRisk": 8, "shareHolderRightsRisk": 8, "overallRisk": 7, "governanceEpochDate": 1727740800, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 2, "previousClose": 48.73, "open": 49.025, "dayLow": 47.075, "dayHigh": 49.525, "regularMarketPreviousClose": 48.73, "regularMarketOpen": 49.025, "regularMarketDayLow": 47.075, "regularMarketDayHigh": 49.525, "beta": 2.216, "forwardPE": -14.631098, "volume": 430325, "regularMarketVolume": 430325, "averageVolume": 421137, "averageVolume10days": 332880, "averageDailyVolume10Day": 332880, "marketCap": 3149103872, "fiftyTwoWeekLow": 9.6, "fiftyTwoWeekHigh": 53.27, "priceToSalesTrailing12Months": 35.563004, "fiftyDayAverage": 46.854, "twoHundredDayAverage": 39.356, "currency": "USD", "enterpriseValue": 2541766144, "profitMargins": -1.78265, "floatShares": 41626009, "sharesOutstanding": 64583800, "sharesShort": 9066772, "sharesShortPriorMonth": 9487586, "sharesShortPreviousMonthDate": 1726185600, "dateShortInterest": 1728950400, "sharesPercentSharesOut": 0.14039999, "heldPercentInsiders": 0.01282, "heldPercentInstitutions": 1.06037, "shortRatio": 19.45, "shortPercentOfFloat": 0.1568, "impliedSharesOutstanding": 65620000, "bookValue": 11.124, "priceToBook": 4.314096, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1719705600, "netIncomeToCommon": -157854000, "trailingEps": -2.41, "forwardEps": -3.28, "pegRatio": -8.56, "enterpriseToRevenue": 28.704, "enterpriseToEbitda": -14.363, "52WeekChange": 3.2771835, "SandP52WeekChange": 0.39389753, "exchange": "NGM", "quoteType": "EQUITY", "symbol": "KYMR", "underlyingSymbol": "KYMR", "shortName": "Kymera Therapeutics, Inc.", "longName": "Kymera Therapeutics, Inc.", "firstTradeDateEpochUtc": 1598016600, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "fe087242-38df-325c-aac8-26165faa63ce", "messageBoardId": "finmb_542085131", "gmtOffSetMilliseconds": -14400000, "currentPrice": 47.99, "targetHighPrice": 106.0, "targetLowPrice": 36.0, "targetMeanPrice": 56.27, "targetMedianPrice": 54.0, "recommendationMean": 1.9, "recommendationKey": "buy", "numberOfAnalystOpinions": 15, "totalCash": 509952992, "totalCashPerShare": 8.258, "ebitda": -176967008, "totalDebt": 88181000, "quickRatio": 8.234, "currentRatio": 8.455, "totalRevenue": 88550000, "debtToEquity": 12.875, "revenuePerShare": 1.358, "returnOnAssets": -0.16038, "returnOnEquity": -0.28179002, "freeCashflow": -89477248, "operatingCashflow": -106129000, "revenueGrowth": 0.553, "grossMargins": -1.36147, "ebitdaMargins": -1.9985001, "operatingMargins": -1.9853799, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-10-28"}]